These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21133674)

  • 1. Modification of CellSensor irf1-bla TF-1 and irf1-bla HEL assays for direct comparison of wild-type JAK2 and JAK2 V617F inhibition.
    Mason JL; Holskin BP; Murray KA; Meyer SL; Wells-Knecht KJ; Ator MA; Angeles TS
    Assay Drug Dev Technol; 2011 Jun; 9(3):311-8. PubMed ID: 21133674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays.
    Qian J; Mason JL; Holskin BP; Murray KA; Meyer SL; Ator MA; Angeles TS
    Assay Drug Dev Technol; 2012 Apr; 10(2):212-7. PubMed ID: 22132729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular LanthaScreen and beta-lactamase reporter assays for high-throughput screening of JAK2 inhibitors.
    Robers MB; Machleidt T; Carlson CB; Bi K
    Assay Drug Dev Technol; 2008 Aug; 6(4):519-29. PubMed ID: 18694336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
    Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
    Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
    Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
    Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
    Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
    J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the structure and function of the pseudokinase domain in JAK2.
    Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
    Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
    Quentmeier H; MacLeod RA; Zaborski M; Drexler HG
    Leukemia; 2006 Mar; 20(3):471-6. PubMed ID: 16408098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
    Dusa A; Mouton C; Pecquet C; Herman M; Constantinescu SN
    PLoS One; 2010 Jun; 5(6):e11157. PubMed ID: 20585391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
    Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
    Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
    Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.
    Sanz A; Ungureanu D; Pekkala T; Ruijtenbeek R; Touw IP; Hilhorst R; Silvennoinen O
    PLoS One; 2011 Apr; 6(4):e18522. PubMed ID: 21533163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
    Lee TS; Ma W; Zhang X; Giles F; Kantarjian H; Albitar M
    Cancer; 2009 Apr; 115(8):1692-700. PubMed ID: 19195039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.
    Liosi ME; Ippolito JA; Henry SP; Krimmer SG; Newton AS; Cutrona KJ; Olivarez RA; Mohanty J; Schlessinger J; Jorgensen WL
    J Med Chem; 2022 Jun; 65(12):8380-8400. PubMed ID: 35653642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.
    Wan S; Coveney PV
    J Chem Inf Model; 2012 Nov; 52(11):2992-3000. PubMed ID: 23033920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
    Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
    Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target.
    Guan H; Lamb ML; Peng B; Huang S; Degrace N; Read J; Hussain S; Wu J; Rivard C; Alimzhanov M; Bebernitz G; Bell K; Ye M; Zinda M; Ioannidis S
    Bioorg Med Chem Lett; 2013 May; 23(10):3105-10. PubMed ID: 23562594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.